```json
{
"content": [
{
"type": "paragraph",
"content": "Over the past 18 months, the Surgical Absorbable Gelatin Sponge industry trends have been reshaped by a wave of strategic consolidation and rapid innovation. In early 2023, Baxter completed its $4.1 billion acquisition of Gelita Medical’s hemostasis portfolio, instantly doubling its gelatin sponge production capacity and securing exclusive supply rights across 12 EU markets. Weeks later, B. Braun’s $120 million minority stake in NanoSpheal (developers of a nanofiber-reinforced gelatin sponge with 30-second hemostasis) signaled a decisive shift toward ultra-rapid absorbable platforms."
},
{
"type": "paragraph",
"content": "Product launches accelerated when SurgiCore USA introduced the first plant-derived cross-linked gelatin sponge—free from bovine or porcine tissue—targeting the 22% of U.S. ASCs that now refuse animal-origin products. Regulatory momentum followed: Health Canada’s July 2023 guidance reclassified absorbable hemostatic sponges as Class III with streamlined 90-day review, prompting three new entrants to file dossiers within Q4."
},
{
"type": "paragraph",
"content": "Enterprise buying patterns have pivoted toward kit-form solutions; hospital GPOs report a 38% YoY increase in contracts bundling gelatin sponges with catheter-delivered applicators, driven by ambulatory surgery growth. Meanwhile, Series A funding for SealFoam Medical’s AI-coated gelatin sponge reached $33 million in February 2024, underscoring investor appetite for data-enabled hemostasis.
}
]
}
```
